This weekly column offers opinions on the latest pharmaceutical industry news.

Among the many questionable tactics Mylan Pharmaceuticals has pursued to boost EpiPen sales has been a surreptitious lobbying campaign to have its device added to a coveted list of preventive services that is maintained by the federal government.

Here’s why this matters: If Mylan succeeds in getting EpiPen on that list, consumers would not have to make copayments, leaving insurers or government agencies to pick up that cost. That sounds like a good deal for patients. But by taking their wallets out of the equation, Mylan minimizes the chance of a public backlash to its pricing. It could likely keep raising the price of EpiPen — largely unnoticed.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • If this kind of proposal comes to fruition, it would broad day light robbery or something more malicious of the US taxpayer. What would be interesting which senator or congress person would support such a robbery.

    I guess profits before ethics are modus operandi. Cheers.

  • The government has the right to take private property if it is in the public interest.

    Mylan Pharmaceuticals should be seized by eminent domain and resold to a company that will agree to a contract setting a reasonable maximum rate of price hikes.

  • It seems by the Mylan logic that any antidote for a poison would also qualify a a preventive measure. Your stand is the correct one – hopefully it will get the attention it deserves.

    • Mylan is doing nothing different from the lobbying tactics Merck used to push through guidelines that now require 12 year old children in DC, Virginia and Rhode Island to be vaccinated with Gardasil against HPV.

    • May I observe that the real point of dispute is not the pathway but the treatment itself. A vaccine is not given after the onset of the disease – they are preventive by definition.

    • Hi Pharmvet1,

      Yes, although Merck initially tried a surreptitious national effort by enlisting Women in Government, a collection of elected officials, and that backfired. The playbook is the same, in any event, although the Mylan school program may have violated antitrust law, which is a different matter.

      Regards
      ed

  • In the midst of this screaming election, this scheme by Mylan may just slip under the radar. Glad to see your article and agree completely this tactic by a company is not only wrong but also unnecessary. Lobbying for laws that require schools to stock their product is another tactic Mylan has undertaken to fill their coffers under the guise of saving lives. And their recent fine is a drop in the bucket of the profit they made using the wrong classification for EpiPen….why aren’t they required to return all the money they overcharged with interest?

Your daily dose of news in health and medicine

Privacy Policy